Findings :
INTRODUCTION
Living habits, cancer and environment changes have become the largest cause of death. Cancer is reflecting a multi-step process, reflecting from acquired defects in genes involved in the mutation or mis-regulation of cell cycle controlling genes and proteins to guide an abnormal control of cell 1 proliferation . Cancer is the second largest cause of mortality in the last decade. Many of the genes involved in cell cycle progression are frequently mutated, leading to uncontrolled cell division. Progression of a cell through the cell cycle is dependent on one family of serine/threonine [2] [3] [4] [5] [6] kinases, called CDKs . The CDK7 is a major constituent of both CDK-activating kinase (CAK) and transcription factor TFIIH, involved in upstream of cell cycle regulatory CDKs and it 8 breast and colon cancers . Hence CDK7 have been actively considered as active targets for anticancer 9 therapy . This knowledge provides information about recent rationale advances for considering the cell cycle and its complexes involved in regulation system as potential targets for design and development of new selective drugs in cancer 10 therapeutics . Targeting of CDK7 receptor is a new approach for the design and development of novel 11 anticancer drugs . Molecular docking studies of all the synthesized compounds 1a-3c into ATP binding site of CDK7 was performed to investigate the ability of these novel derivatives to inhibit these tumorogenic agents.
EXPERIMENTAL 2.1 Materials and Methods :

Synthesis :
All the used reagents were purchased from SigmaAldrich, HiMedia Laboratories Ltd. and LobaChemie Pvt. Ltd. and were used without further purification. Shimadzu BL220H analytical balance was used for the weighing purposes. The progress of the reactions were monitored by TLC using ether/chloroform as a mobile phase on pre-coated Merck TLC plates in iodine chamber. All melting points were recorded on Stuart melting point apparatus (SMP-30) with open glass capillary tube and were uncorrected. IR spectra of compounds were recorded with KBr on a Bruker FT-IR 1 spectrophotometer. H NMR spectra were obtained in DMSO on 400 MHz Bruker Advance II NMR spectrometer using TMS (d=0) as an internal standard.
Molecules for the present study were synthesised via A mixture of DEAD or DMAD (1 mmol) and hydrazinehydrate (1 mmol) was stirred for 4-5 min at room temperature. Then 20% ethanol (5 mL), malononitrile (1 mmol) and substituted isatin (1 mmol) were added and stirring mixture at reflux temperature for 10 min. Finally, the precipitated product was filtered and washed with distilled water 12 and dried to get pyrano [2, 3-c] pyrazole derivatives .
A 50 mL flask charged with hydrazine (1.2 mmol), ß-keto ester (1 mmol), substituted isatin (1 mmol), malononitrile (1 mmol) and L-proline (0.1 mmol) was stirred at 80 °C in water (5 ml. The completion of the reaction was monitored by TLC; the reaction mixture was cooled to room temperature. Then the precipitated product was filtered and washed with water and cold ethanol to afford the pure product as 13 a solid in good to excellent yields .
MOLECULAR DOCKING
BIOLOGICAL EVALUATION 2.4.1 Cell culture and treatments :
Docking studies of all designed compounds were performed by downloading 3-dimensional crystal structure of CDK7, retrieved from Protein Data Bank (PDB ID: 1UA2) and further refined for protein preparation by removing water molecules and then hydrogen was added and pocket modelling was carried out using proviz module of VLife MDS 4.3 software. The designed spiropyranopyarazole derivatives were drawn in 2D and then converted into 3D. Finally energy was minimized using Merck Molecular Force Field (MMFF) and residues at surrounding of the active pocket at a distance less than 5 Å from reference ligand surface were marked. 
Anticancer activity :
Evaluation of anticancer activity of synthesized compounds was carried out using MTT assay (Breast MCF7 cell lines). MTT assay was carried out using 96-well plates (total volume of media was 200 µL/well). After the treatments cells were washed with 1× PBS and were mixed with 100µL/mL well of MTT (5 mg in 10 mL of 1×PBS) and finally incubated at room temperature for 24hrs to allow formation of formazan crystals. Each well was then mixed with 100µL of DMSO to dissolve the crystals 15, 16 followed by ELISA readings at 570 nm . Anticancer activity was evaluated as a function of percent inhibition with respect to 5-FU as a standard and was calculated by the following formula:
Multicomponent reactions used in the synthesis of the target compounds are illustrated in Fig.1 
Docking studies :
We find out the binding mode for all the synthesized compounds, docking studies were conducted using VLife MDS 4.3 ( figure 2) . From the docking procedures we were satisfied with the all designed compounds, the target compounds were subjected to V Life MDS 4. 
Pharmacokinetic study :
Predicted percent oral absorption of all synthesized compounds was calculated by considering total polar surface area (TPSA). Calculated predicted percent oral absorption by using following formula Predicted percent oral absorption = 109 -(TPSA × 0.345) × 100. All derivatives showed acceptable Lipinski parameters and oral absorption within 61% 17, 18, 19 and 75% as shown table no. 3 . 
